SPRYCEL (dasatinib, BMS-354825; Bristol-Myers Squibb, Princeton, NJ), a multiple kinase
inhibitor, is currently approved to treat chronic myelogenous leukemia and Philadelphia …

Background: According to the most recent data, an estimated 17.1% of children in the United
States are obese. We found no published studies documenting the prevalence of obesity in …

Saxagliptin is a potent, selective, reversible dipeptidyl peptidase 4 (DPP4) inhibitor specifically
designed for extended inhibition of the DPP4 enzyme and is currently under development …

The contribution of organic anion transporter OAT2 (SLC22A7) to the renal tubular secretion
of creatinine and its exact localization in the kidney are reportedly controversial. In the …

Aim To determine the absolute oral bioavailability (F po ) of saxagliptin and dapagliflozin using
simultaneous intravenous 14 C‐microdose/therapeutic oral dosing (ivmicro + oraltherap). …

N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
(dasatinib, Sprycel, BMS-354825; Bristol-Myers Squibb, …

In a recent study, limited to South Asian Indian subjects (n = 12), coproporphyrin (CP) I and
CPIII demonstrated properties appropriate for an organic anion-transporting polypeptide (…

Dasatinib [N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide;
BMS-354825] is a potent and broad-spectrum …

Background: Although pedobarography has been widely used in quantitative clinical gait
analysis for children, the collection, processing, analysis, and interpretation of the data vary …

Saxagliptin is a potent dipeptidyl peptidase-4 inhibitor approved for the treatment of type 2
diabetes mellitus. The pharmacokinetics and disposition of [ 14 C]saxagliptin were …